Treatment	B:C0087111
with	O
high	O
dose	O
of	O
atorvastatin	B:C0286651
reduces	O
vascular	B:C0178324
injury	I:C0178324
in	O
diabetic	B:C0011849
rats	B:C0086893
.	O

Previous	O
reports	O
showed	O
conflicting	O
results	O
regarding	O
the	O
treatment	B:C0087111
effects	O
of	O
statin	B:C0360714
on	O
Diabetes	B:C0011849
mellitus	I:C0011849
(	O
Diabetes	B:C0011849
mellitus	I:C0011849
)	O
.	O

We	O
investigated	O
how	O
treatment	B:C0087111
with	O
high	O
dose	O
of	O
atorvastatin	B:C0286651
affects	O
the	O
impaired	O
vascular	B:C0232337
function	I:C0232337
in	O
diabetic	B:C0011849
rats	B:C0086893
.	O

Atorvastatin	B:C0286651
(	O
80mg	O
/	O
kg/	O
day	O
,	O
oral	O
gavage	O
,	O
4	O
weeks	O
)	O
or	O
its	O
vehicle	B:C0042444
was	O
administered	O
to	O
male	O
control	O
or	O
streptozotocin	B:C0038432
(	O
streptozotocin	B:C0038432
)	O
-	O
induced	O
diabetic	B:C0011849
rats	B:C0086893
.	O

Aortic	B:C0506947
segments	I:C0506947
were	O
used	O
to	O
investigate	O
the	O
vascular	O
reactivity	O
,	O
protein	B:C1171362
expression	I:C1171362
of	O
cyclooxygenase	B:C0387583
-	I:C0387583
2	I:C0387583
(	O
cyclooxygenase	B:C0387583
-	I:C0387583
2	I:C0387583
)	O
and	O
nicotinamide	B:C1417769
adenine	I:C1417769
dinucleotide	I:C1417769
phosphate	I:C1417769
oxidase	I:C1417769
(	I:C1417769
NADPH	I:C1417769
oxidase	I:C1417769
)	I:C1417769
1	I:C1417769
(	O
NOX1	B:C1417769
)	O
and	O
superoxide	B:C0038836
anions	I:C0038836
levels	O
.	O

Atorvastatin	B:C0286651
treatment	B:C0087111
did	O
not	O
affect	O
glycemia	B:C0392201
levels	I:C0392201
.	O

In	O
diabetic	B:C0011849
rats	B:C0086893
,	O
the	O
vascular	O
reactivity	O
to	O
phenylephrine	B:C0031469
increased	O
compared	O
with	O
controls	O
and	O
the	O
atorvastatin	B:C0286651
treatment	B:C0087111
reduced	O
this	O
response	O
.	O

Removal	O
of	O
the	O
endothelium	B:C0014257
increased	O
the	O
response	O
to	O
phenylephrine	B:C0031469
in	O
control	O
rats	O
,	O
but	O
not	O
in	O
the	O
diabetic	O
group	O
.	O

Atorvastatin	B:C0286651
increased	O
the	O
endothelial	O
modulation	O
in	O
diabetic	B:C0011849
rats	B:C0086893
.	O

L-	B:C0083536
NAME	I:C0083536
(	O
100μM	O
)	O
increased	O
the	O
reactivity	O
in	O
all	O
groups	O
,	O
but	O
this	O
effect	O
was	O
greater	O
in	O
atorvastatin	B:C0286651
-	O
treated	O
diabetic	B:C0011849
rats	B:C0086893
.	O

Indomethacin	B:C0021246
(	O
10μM	O
)	O
and	O
NS398	B:C1567346
(	O
1μM	O
)	O
decreased	O
the	O
contractile	B:C1511498
response	O
in	O
diabetic	B:C0011849
rats	B:C0086893
and	O
atorvastatin	B:C0286651
reversed	O
these	O
effects	O
,	O
without	O
changing	O
cyclooxygenase	B:C0387583
-	I:C0387583
2	I:C0387583
expression	B:C1171362
.	O

Apocynin	B:C0050465
(	O
30μM	O
)	O
decreased	O
the	O
phenylephrine	B:C0031469
response	O
in	O
diabetic	B:C0011849
rats	B:C0086893
,	O
which	O
also	O
showed	O
increased	O
NOX1	B:C1417769
and	O
superoxide	B:C0038836
anions	I:C0038836
;	O
these	O
effects	O
were	O
prevented	O
by	O
atorvastatin	B:C0286651
treatment	B:C0087111
.	O

The	O
results	O
suggest	O
that	O
treatment	B:C0087111
with	O
high	O
dose	O
of	O
atorvastatin	B:C0286651
,	O
independent	O
of	O
glycemia	B:C0005802
,	O
improves	O
endothelial	B:C0014257
function	O
in	O
aortas	B:C0003483
from	O
diabetic	B:C0011849
rats	B:C0086893
by	O
reducing	O
the	O
constrictor	B:C0033554
prostanoids	I:C0033554
derived	O
from	O
cyclooxygenase	B:C0387583
-	I:C0387583
2	I:C0387583
and	O
by	O
reducing	O
the	O
oxidative	B:C0242606
stress	I:C0242606
by	O
NADPH	B:C0068355
oxidase	I:C0068355
,	O
as	O
well	O
as	O
a	O
possible	O
increasing	O
of	O
nitric	B:C0028128
oxide	I:C0028128
participation	O
.	O

